Zobrazeno 1 - 10 of 86 pro vyhledávání: '"Kath D. Watson"'
1
O32 Serious infection with tocilizumab compared to TNF-inhibitors and other bDMARDS in rheumatoid arthritis patients: does line of therapy matter?
Autor: Kimme L. Hyrich, Kim Lauper, Kath D. Watson, Lianne Kearsley-Fleet, Rebecca Davies, Mark Lunt
Publikováno v: Rheumatology. 60
Background/Aims In the real-world, tocilizumab is prescribed to a population of patients different from those prescribed TNF-inhibitors, often older with longer disease duration, worse functional status and more previous b- or tsDMARDs. The aim of th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce5a6677df91a502161c41ba75a94d72
https://doi.org/10.1093/rheumatology/keab246.031
Zobrazit plný text záznamu
2
O27 Early experience with JAK inhibitor prescribing in the UK: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA)
Autor: Mark Lunt, Kath D. Watson, Kimme L. Hyrich, Lianne Kearsley-Fleet, Jennifer Page, Rebecca Davies
Publikováno v: Rheumatology. 59
Background In 2017, a new class of oral disease modifying anti-rheumatic drugs (DMARDs), janus kinase inhibitors (JAKi), were licensed for rheumatoid arthritis (RA): baricitinib and tofacitinib. In the UK, they are approved for use in patients with h
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::732d78087da0b6c6f43840d6d51dba15
https://doi.org/10.1093/rheumatology/keaa110.026
Zobrazit plný text záznamu
3
Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
Autor: Mark Lunt, Kath D. Watson, Lianne Kearsley-Fleet, Mari Kihara, Kimme L. Hyrich, Rebecca Davies, Deborah P M Symmons
Publikováno v: Clinical Rheumatology
Kihara, M, Davies, R, Kearsley-Fleet, L, Watson, K, Lunt, M, Symmons, D & Hyrich, K 2017, ' Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: An observational study from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis ', Clinical Rheumatology, vol. 36, no. 2, pp. 241-250 . https://doi.org/10.1007/s10067-016-3485-5
The aims of the present study are to describe the characteristics of rheumatoid arthritis (RA) patients selected for tocilizumab (TCZ), compare the “real-world” effectiveness of TCZ and tumour necrosis factor inhibitors (TNFi) when used as a firs
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efe5cca61a224a4835813d6f7519d05b
http://europepmc.org/articles/PMC5290047
Zobrazit plný text záznamu
4
Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Autor: P A Sanders, Kimme L Hyrich, Kath D. Watson, Bev Harrison, Deborah P M Symmons, Romela Benitha, Peter Klimiuk, Sheila O’Reilly, Nicola Maiden, Shane Clarke, Lianne Kearsley-Fleet, Ian Griffiths, David A. Walsh, Marwan Bukhari, Paul D. Thompson, Ernest Choy, Paul Emery, Rikki Abernethy, Hilary A Capell, Ronald Jubb, Susan Knight, Mark Lunt, Amanda Coulson, Rhian Mair Goodfellow, Tom Price, David Scott, Laura Chadwick, Nina Brown, Andrew Hassell, A J Taggart, Neil Hopkinson, Fiona McCrae, Ian N. Bruce, Sandra Green, Lesley Hordon, George D. Kitas, Kimme L. Hyrich, Duncan Porter
Publikováno v: BSRBR-RA Control Centre Consortium 2019, ' Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis ', Rheumatology (Oxford) . https://doi.org/10.1093/rheumatology/kez277
BSRBR-RA Control Centre Consortium 2019, ' Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis ', Rheumatology (Oxford, England) . https://doi.org/10.1093/rheumatology/kez277
Objectives To compare cervical screening attendance and cytology (high- and low-grade cervical dysplasia [HGCD and LGCD]) between women with RA and the English general population and between biologic DMARD (bDMARD)-naïve and exposed women. Methods T
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393fbccc224cacdea428269ea645c5b0
https://research.manchester.ac.uk/en/publications/74caffc6-71d5-4054-9c91-8d6e8426008d
Zobrazit plný text záznamu
5
AB0434 EARLY EXPERIENCE WITH JAK INHIBITOR PRESCRIBING IN THE UK: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS (BSRBR-RA)
Autor: Mark Lunt, Jennifer Page, Lianne Kearsley-Fleet, Kath D. Watson, Rebecca Davies, Kimme L. Hyrich
Publikováno v: Abstracts Accepted for Publication.
Background: In 2017 a new class of oral disease modifying anti-rheumatic drugs (DMARDs), janus kinase inhibitors (JAKi), were licensed for rheumatoid arthritis (RA): baricitinib and tofacitinib. In the UK, they are approved for use in patients with h
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad1e14a905cbbffa82cd2fb9e596244f
https://doi.org/10.1136/annrheumdis-2019-eular.508
Zobrazit plný text záznamu
6
SAT0141 FREQUENCY AND REASONS FOR SWITCHING BACK TO BIOLOGIC ORIGINATOR FOLLOWING INITIAL SWITCH TO BIOLOGIC BIOSIMILAR
Autor: Lianne Kearsley-Fleet, Mark Lunt, Rebecca Davies, Kimme L. Hyrich, Kath D. Watson
Publikováno v: SATURDAY, 15 JUNE 2019.
Background: Since February 2015, a number of biosimilar drugs have been introduced for treatment of rheumatoid arthritis (RA) in the UK. Biosimilars are required to have no clinically meaningful differences in efficacy or safety from the originator p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::757101236bffc52cc1c192607867ff70
https://doi.org/10.1136/annrheumdis-2019-eular.6845
Zobrazit plný text záznamu
9
Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register
Autor: Deborah P M Symmons, Jon Packham, Lianne Kearsley-Fleet, Kath D. Watson, Louise K. Mercer, Karen M Fagerli, Kimme L. Hyrich
Publikováno v: Fagerli, K M, Kearsley-Fleet, L, Mercer, L K, Watson, K, Packham, J, Symmons, D P M, Hyrich, K L & British Society for Rheumatology Biologics Register 2019, ' Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register ', Rheumatology (Oxford, England), vol. 58, no. 1, pp. 80-85 . https://doi.org/10.1093/rheumatology/key241
Rheumatology (Oxford, England)
Objective: The aim of this study was to compare the incidence of cancer and all-cause and cause-specific mortality rates among a cohort of patients with severe PsA receiving TNF inhibitor (TNFi) with those of the general UK population.Methods: Cancer
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a63b646c03ead24508e84b80b25736af
https://research.manchester.ac.uk/en/publications/b8eb5210-6ecc-4fd8-ba0c-2074bb40d8ca
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje